NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Netherlands Cancer Institute
University of Nebraska
University of Wisconsin, Madison